Germany-based specialty pharmaceutical company Novaliq has enrolled the first patient in a Phase ll clinical trial of NOV03 to treat dry eye disease (DED).

The SEECASE trial is a multi-centre, randomised, double-masked, saline-controlled study examining the effect of NOV03 at two different dosing regimens on signs and symptoms of DED.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

During the trial, NOV03 will be assessed in two dosing regimens, two and four instillations per day.

The trial represents Novaliq’s second late-stage clinical programme in the US, and is expected to provide top-line data by the second half of this year.

Novaliq Clinical Development vice-president Sonja Krösser said: “The initiation of this Phase ll US trial represents another significant clinical milestone that advances our clinical dry eye programme, and moves us a step closer to bringing novel dry eye treatments to market that meet unmet needs.

“We are optimistic that we will see similar outcomes in the SEECASE Phase ll trial.”

“Earlier studies have demonstrated a highly favourable safety and efficacy profile in patients with DED, particularly for evaporative DED and MGD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are optimistic that we will see similar outcomes in the SEECASE Phase ll trial.”

Novaliq further noted that its NOV03 is specifically designed for patients with evaporative dry eye disease caused by meibomian gland dysfunction.

NOV03 is also capable of immediately stabilising the lipid layer to prevent its excessive evaporation.

With further penetration into the meibomian glands, the solution dissolves meibomian lipids and eventually helps to improve the gland functionality.